X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
Other Suppliers
0
0
USA (Orange Book)
Europe
Canada
0
Australia
0
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
Details:
Spravato (esketamine) is the S-enantiomer of racemic ketamine and is a non-selective, non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor. It is being developed for treating resistant major depressive disorder.
Lead Product(s): Esketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Spravato
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2023
Details:
Spravato® (esketamine) is the S-enantiomer of racemic ketamine, is a non-selective, non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor. It is being developed for treating resistant major depressive disorder.
Lead Product(s): Esketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Spravato
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2023
Details:
First findings from the study support the short- and long-term use of SPRAVATO® (esketamine) nasal spray in adults living with treatment-resistant major depressive disorder in achieving remission and remaining relapse free.
Lead Product(s): Esketamine Hydrochloride,Undisclosed
Therapeutic Area: Psychiatry/Psychology Product Name: Spravato
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2022
Details:
Spravato® (esketamine) is the S-enantiomer of racemic ketamine and is a non-selective, non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor. It is being developed for treating resistant major depressive disorder.
Lead Product(s): Esketamine Hydrochloride,Duloxetine
Therapeutic Area: Psychiatry/Psychology Product Name: Spravato
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2022
Details:
Zilentin will purchase from Altamira, an option that entitles Zilentin to acquire Altamira’s remaining legacy assets in inner ear therapeutics, including AM-101 (tinnitus), AM-111, Keyzilen and Sonsuvi (hearing loss) and AM-125 (vertigo), for an upfront payment upon exercise.
Lead Product(s): Esketamine Hydrochloride
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Keyzilen
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Altamira Therapeutics
Deal Size: $82.0 million Upfront Cash: $27.0 million
Deal Type: Divestment October 21, 2022
Details:
SPRAVATO® (esketamine) CIII nasal spray is a nonselective, noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor – an ionotropic glutamate receptor.
Lead Product(s): Esketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Spravato
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Delic Corp
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
The first discussion titled Ketamine and Esketamine, is s-enantiomer of ketamine. Ketamine is a mixture of two enantiomers (mirror image molecules), for the treatment of depression in adults who have tried other antidepressant medicines .
Lead Product(s): Esketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2022
Details:
SPRAVATO® (esketamine) CIII nasal spray is a non-selective, non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor – an ionotropic glutamate receptor. Esketamine is safe and effective, especially when combined with ongoing psychiatric support.
Lead Product(s): Esketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Spravato
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2021
Details:
KETABET™, a patented combination formulation of FDA-approved ketamine and betaine anhydrous, has been shown in research to enhance the antidepressant effect while having the potential to reduce the known negative side effects of ketamine significantly.
Lead Product(s): Esketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Ketabet
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2021
Details:
The proposed ketamine and KETABET™ MN patch offer a potential game-changing therapeutic solution for various unmet medical needs.
Lead Product(s): Esketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Ketabet
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: The Queen's University of Belfast
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 24, 2021
Details:
The European Commission (EC) has authorised the expanded use of Janssen’s Spravato (esketamine nasal spray), co-administered with oral antidepressant therapy in adults with a moderate to severe episode of major depressive disorder (MDD).
Lead Product(s): Esketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Spravato
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2021
Details:
The European marketing authorisation application was based on the Phase 3 double-blind, randomised, placebo controlled, multicentre ASPIRE I & II clinical studies SPRAVATO®▼ (Esketamine Nasal Spray) in combination with comprehensive standard of care.
Lead Product(s): Esketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Spravato
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2020
Details:
Spravato® (esketamine) is the S-enantiomer of racemic ketamine and is a non-selective, non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor. It is being developed for treating resistant major depressive disorder.
Lead Product(s): Esketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Spravato
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2020
Details:
Spravato® (esketamine) is the S-enantiomer of racemic ketamine and is a non-selective, non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor. It is being developed for treating resistant major depressive disorder.
Lead Product(s): Esketamine Hydrochloride,Duloxetine
Therapeutic Area: Psychiatry/Psychology Product Name: Spravato
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 22, 2020
Details:
Falkieri (esketamine dry powder inhalation) is the antagonist of N-methyl-D-aspartate (NMDA) receptor. It is being developed for Treatment-Resistant Bipolar Depression.
Lead Product(s): Esketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Falkieri
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
